Skip to main content

Update on the use of montelukast in pediatric asthma

Buy Article:

$39.50 plus tax (Refund Policy)

Abstract:

Cysteinyl leukotrienes are inflammatory bioactive lipids produced by various cells. They are present in increased amounts in airway secretions of all different asthma phenotypes and can induce all the inflammatory changes observed in the airways of asthmatic patients. For this reason, an attempt to inhibit the actions of these mediators through the use of cysteinyl receptor antagonists appears rational. Montelukast belongs to this new class of drugs, which has been proved effective in asthmatic children and its safety profile is comparable with that of placebo. The major advantages of this drug are its once-daily oral administration, which increases adherence to the therapeutic regimen; its long-term persistent efficacy in the prevention of exercise-induced bronchoconstriction; its possible preventive activity on viral-induced asthma exacerbations; and its complementary and additive effects when used with inhaled corticosteroids. As established for all drugs commonly used in the treatment of asthma, there is an interindividual variability also in response to montelukast. Therefore, it is important that caregivers evaluate treatment effect objectively in every asthmatic child to provide the single patient with a therapeutic regimen allowing the best quality of life.

Document Type: Research Article

DOI: https://doi.org/10.2500/aap.2006.27.2883

Publication date: 2006-07-01

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • www.AJRA.com
  • www.AllergyandRhinology.com
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more